Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Administered to all patients for a minimum of 4 cycles for 12 weeks.

Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.

Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Administered to all premenopausal patients.